Osteopontin expression in cardiomyocytes induces dilated cardiomyopathy
Related Experiment Video
Updated: Jun 15, 2026

Sarcomere Shortening of Pluripotent Stem Cell-Derived Cardiomyocytes using Fluorescent-Tagged Sarcomere Proteins.
Published on: March 3, 2021
Marie-Ange Renault1, Fanny Robbesyn, Patricia Réant
1INSERM U828, Ave. du Haut Lévêque, Pessac, France.
Insights
Osteopontin (OPN) overexpression in the heart causes chronic myocarditis, leading to dilated cardiomyopathy and heart failure in mice. This suggests OPN is a potential therapeutic target for heart disease.
Area of Science:
- Cardiovascular Research
- Immunology
- Molecular Biology
Background:
- Inflammatory processes are key in myocarditis, dilated cardiomyopathy, and heart failure.
- Osteopontin (OPN) expression is elevated in heart disease, but its role is unclear.
Purpose of the Study:
- To investigate the role of osteopontin (OPN) in the development of heart disease.
Main Methods:
- Generated transgenic mice (MHC-OPN) with cardiac-specific OPN overexpression.
- Conducted electrocardiography, echocardiography, and histological analysis.
- Assessed for autoantibodies in serum.
Main Results:
- MHC-OPN mice exhibited premature death, conduction defects, and left ventricular dysfunction.
- Histology revealed cardiomyocyte loss, fibrosis, and T-cell infiltration with Th1 polarization.
- No autoantibodies against OPN or cardiac proteins were detected.
Conclusions:
- Cardiac OPN expression drives T-cell recruitment and activation, causing chronic myocarditis.
- This leads to myocyte destruction and dilated cardiomyopathy.
- OPN represents a potential therapeutic target for limiting heart failure progression.
Background:
Inflammatory processes play a critical role in myocarditis, dilated cardiomyopathy, and heart failure. The expression of the inflammatory chemokine osteopontin (OPN) is dramatically increased in cardiomyocytes and inflammatory cells during myocarditis and heart failure in human and animals. However, its role in the development of heart diseases is not known.
Methods And Results:
To understand whether OPN is involved in cardiomyopathies, we generated a transgenic mouse (MHC-OPN) that specifically overexpresses OPN in cardiomyocytes with cardiac-specific promoter-directed OPN expression. Young MHC-OPN mice were phenotypically indistinguishable from their control littermates, but most of them died prematurely with a half-life of 12 weeks of age. Electrocardiography revealed conduction defects. Echocardiography showed left ventricular dilation and systolic dysfunction. Histological analysis revealed cardiomyocyte loss, severe fibrosis, and inflammatory cell infiltration. Most of these inflammatory cells were activated T cells with Th1 polarization and cytotoxic activity. Autoantibodies against OPN, cardiac myosin, or troponin I, were not found in the serum of MHC-OPN mice.
Conclusions:
These data show that OPN expression in the heart induces in vivo T-cell recruitment and activation leading to chronic myocarditis, the consequence of which is myocyte destruction and hence, dilated cardiomyopathy. Thus, OPN might therefore constitute a potential therapeutic target to limit heart failure.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Heart Failure II: Pathophysiology

